TNF and ataxia telangiectasia: Among patients in the AT-IR subgroup, risankizumab induction and maintenance therapy were generally more effective than placebo at achieving clinical and endoscopic outcomes, irrespective of the prior AT number (1, ≥ 2), mechanism of action (TNF inhibitor, vedolizumab, JAK inhibitor), or specific TNF inhibitor type (infliximab, adalimumab, golimumab).